Apramycin

Apramycin (Nebramycin II) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic[1][2][3].

Product Specifications

CAS Number

[37321-09-8]

Product Name Alternative

Nebramycin II

UNSPSC

12352005

Hazard Statement

H315-H410

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/apramycin.html

Solubility

10 mM in DMSO

Smiles

O[C@H]1[C@](O[C@H](O[C@@]([C@H](C[C@H]2N)N)([H])[C@@H]([C@H]2O)O)[C@H](N)C3)([H])[C@@]3([H])O[C@H](O[C@@]([C@@H]([C@@H](O)[C@@H]4N)O)([H])O[C@@H]4CO)[C@H]1NC

Molecular Formula

C21H41N5O11

Molecular Weight

539.58

Precautions

P264-P273-P280-P302+P352-P362+P364-P391-P501

References & Citations

[1]Juhas M, et al. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii. J Antimicrob Chemother. 2019;74 (4) :944-952.|[2]Meyer M, et al. In vivo efficacy of apramycin in murine infection models. Antimicrob Agents Chemother. 2014 Nov;58 (11) :6938-41. |[3]Becker K, et al. Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis. EBioMedicine. 2021 Nov;73:103652.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

Phase 1

Citation 01

J Adv Res. 2024 Jun 27:S2090-1232 (24) 00256-X.|Acta Pharm Sin B. 2023 Sep;13 (9) :3678-3693.|Nat Microbiol. 2023 Mar;8 (3) :410-423.|Nat Microbiol. 2025 Nov;10 (11) :2875-2891.